Peter A Ljubenkov
Overview
Explore the profile of Peter A Ljubenkov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
VandeVrede L, La Joie R, Horiki S, Mundada N, Koestler M, Hwang J, et al.
Acta Neuropathol
. 2025 Feb;
149(1):17.
PMID: 39945923
No abstract available.
2.
Rajbanshi B, Prufer Q C Araujo I, VandeVrede L, Ljubenkov P, Staffaroni A, Heuer H, et al.
Alzheimers Dement (Amst)
. 2025 Jan;
17(1):e70078.
PMID: 39886325
Introduction: Plasma amyloid beta/amyloid beta (Aβ/Aβ) and phosphorylated tau217 (p-tau217) identify individuals with primary Alzheimer's disease (AD). They may detect AD co-pathology in the setting of other primary neurodegenerative diseases,...
3.
Wise A, Li J, Yamakawa M, Loureiro J, Peterson B, Worringer K, et al.
Neurology
. 2024 Jul;
103(3):e209585.
PMID: 38959435
Background And Objectives: Identification of fluid biomarkers for progressive supranuclear palsy (PSP) is critical to enhance therapeutic development. We implemented unbiased DNA aptamer (SOMAmer) proteomics to identify novel CSF PSP...
4.
Samudra N, Fischer D, Lenio S, Lario Lago A, Ljubenkov P, Rojas J, et al.
Alzheimers Dement
. 2024 Mar;
20(5):3334-3341.
PMID: 38539061
Introduction: Lewy body disease (LBD) is a common primary or co-pathology in neurodegenerative syndromes. An alpha-synuclein seed amplification assay (αSyn-SAA) is clinically available, but clinical performance, especially lower sensitivity in...
5.
VandeVrede L, La Joie R, Horiki S, Mundada N, Koestler M, Hwang J, et al.
Acta Neuropathol
. 2023 Sep;
146(5):777-781.
PMID: 37725166
No abstract available.
6.
Ljubenkov P, Rabinovici G
Nat Med
. 2023 May;
29(6):1320-1321.
PMID: 37198457
No abstract available.
7.
VandeVrede L, La Joie R, Thijssen E, Asken B, Vento S, Tsuei T, et al.
JAMA Neurol
. 2023 Apr;
80(5):495-505.
PMID: 37010841
Importance: Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in...
8.
Asken B, Ljubenkov P, Staffaroni A, Casaletto K, VandeVrede L, Cobigo Y, et al.
J Neurol Neurosurg Psychiatry
. 2023 Mar;
94(7):541-549.
PMID: 36977552
Background: Measuring systemic inflammatory markers may improve clinical prognosis and help identify targetable pathways for treatment in patients with autosomal dominant forms of frontotemporal lobar degeneration (FTLD). Methods: We measured...
9.
Friedberg A, Ramos E, Yang Z, Bonham L, Yokoyama J, Ljubenkov P, et al.
Front Neurol
. 2022 Jul;
13:909944.
PMID: 35812083
-related leukoencephalopathy is an autosomal dominant neurodegenerative disease caused by mutations in the tyrosine kinase domain of the colony stimulating factor 1 receptor (CSF1R). Several studies have found that hematogenic...
10.
Toller G, Cobigo Y, Ljubenkov P, Appleby B, Dickerson B, Domoto-Reilly K, et al.
Neurology
. 2022 May;
99(5):e488-e499.
PMID: 35584922
Background And Objectives: Changes in social behavior are common symptoms of frontotemporal lobar degeneration (FTLD) and Alzheimer disease syndromes. For early identification of individual patients and differential diagnosis, sensitive clinical...